$AVPT

AvePoint chief legal officer sells $141,100 in stock

AvePoint's CLO, Brian Michael Brown, sold 10,000 shares for $141,100 on September 30, 2026, under a 10b5-1 plan. AVPT stock has risen 54% in six months. Analysts from BMO, D.A. Davidson, Cantor Fitzgerald, and Stephens have issued positive ratings and price targets, citing strong growth prospects in AI-driven data management.

Original reporting
Published Oct 13, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 2:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AVPT
Bearish
medium confidence
Mentioned
$AVPT
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AVPTBearishLow
01

Why it matters

Primary disclosure of a Form 4 insider sale; modest novelty with limited price impact.

02

Market read

The filing provides a fresh, albeit small, data point for traders monitoring insider activity; broader market relevance is limited.

03

What to watch

Analyst upgrades and price‑target raises mentioned in the article may offset any negative sentiment from the insider sale.

Relevance 4/10Novelty 4/10Timing: immediate upon filing release

Background

The article reports an insider sale and summarizes recent analyst coverage that is not new information.

Company-level read

Ticker impact

$AVPTBearishMedium confidence
Context

Chief Legal Officer Brian M. Brown sold 10,000 AVPT shares for $141,100 under a Rule 10b5‑1 plan, disclosed in a Form 4 filing.

Expected impact

likely slight downward pressure as investors price the insider divestiture

Evidence & confidence

C‑level insider sales, even modest, are often interpreted as a lack of confidence; the amount is small relative to float, so impact is limited.

Market effects

Minimal effect on the broader data‑management software sector; AVPT remains a small cap within the industry.

U.S. market only; no notable regional ripple.

Low; the filing does not influence global market dynamics.

Counterpoint

The sale could be purely liquidity‑driven under the pre‑established 10b5‑1 plan, not a bearish signal.

Key entities

  • Brian M. Brown

    Chief Legal Officer and Director of AvePoint, Inc.

  • AvePoint, Inc.

    Provider of data‑management solutions, ticker AVPT.

Related articles

$AVPTHigh

Why is Avepoint stock rallying today?

Avepoint (AVPT) stock rose 4.1% after S&P Dow Jones Indices announced it will join the S&P SmallCap 600 index on November 2, replacing LXP Industrial Trust. The move is driven by expected buying from passive funds tracking the index. AVPT reached a 52-week high of $17.16, up 94% from its low.

$AVPTMedAI 9/10

AvePoint (AVPT) Q2 2026 Earnings Call Transcript

AvePoint (AVPT) reported Q2 2026 revenue of $124.5M, up 22% YoY, with SaaS revenue $98.5M (79% of total). Total ARR was $465.1M (+27%), net new ARR $29.9M, and GAAP operating margin 8.2%. Full-year guidance: ARR $522.1M-$528.1M and revenue $508.5M-$512.5M. The company also spent $50M on share repurchases in Q2.

$AVPTHighAI 9/10

AvePoint lifts annual recurring revenue guidance after Q2

AvePoint reported Q2 2026 revenue of $124.5M and raised full-year annual recurring revenue guidance. SaaS revenue was $98.5M, up 27% y/y, and ARR ended at $465.1M, up 27%. Q3 revenue is forecast at $128.2M to $130.2M, and full-year ARR at $522.1M to $528.1M. The company cited demand for AI governance.

$AVPTHigh

AvePoint Announces Second Quarter 2026 Financial Results

AvePoint, Inc. (AVPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 AvePoint Announces Second Quarter 2026 Financial Results Second quarter SaaS revenue of $98.5 million, representing 27% year-over-year growth, 26% on a constant currency basis Second quarter Total revenue of $124.5 million, representing 22% year-over-year growth, 21%